{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:20:05Z","timestamp":1790889605685,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3503,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Yakult Honsha Co., Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1093\/annonc\/mdp464","type":"journal-article","created":{"date-parts":[[2009,10,30]],"date-time":"2009-10-30T01:57:09Z","timestamp":1256867829000},"page":"1001-1005","source":"Crossref","is-referenced-by-count":104,"title":["Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)"],"prefix":"10.1016","volume":"21","author":[{"given":"W.","family":"Koizumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Takiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Fuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tsuburaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdp464_bb0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P","article-title":"Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer","volume":"72","author":"Murad","year":"1993","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp464_bb0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/oxfordjournals.annonc.a058778","article-title":"Initial or delayed chemotherapy with best supportive care in advanced gastric cancer","volume":"5","author":"Glimelius","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp464_bb0020","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/bjc.1995.114","article-title":"Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer","volume":"71","author":"Pyrh\u00f6nen","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdp464_bb0025","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/sj.bjc.6690350","article-title":"Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial","volume":"80","author":"Waters","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdp464_bb0030","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp464_bb0035","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/annonc\/mdn717","article-title":"Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized phase III noninferiority trial","volume":"20","author":"Kang","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp464_bb0040","first-page":"921","article-title":"Examination of antitumor activities of platinum complexes of 1,2-diaminocyclohexane isomers and their related complexes","volume":"67","author":"Kidani","year":"1976","journal-title":"Gann"},{"key":"10.1093\/annonc\/mdp464_bb0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdp464_bb0050","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al-Batran","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp464_bb0055","first-page":"1705","article-title":"Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil","volume":"21","author":"Kato","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdp464_bb0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdp464_bb0065","article-title":"Multicenter phase III comparison of cisplatin\/S-1 (CS) with cisplatin\/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS)","author":"Ajani","year":"2009","journal-title":"Gastrointestinal Cancers Symposium"},{"key":"10.1093\/annonc\/mdp464_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdp464_bb0075","article-title":"Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912)","volume":"25","author":"Boku","year":"2007","journal-title":"J Clin Oncol(Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdp464_bb0080","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/sj.bjc.6604271","article-title":"Phase I\/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer","volume":"98","author":"Yamada","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdp464_bb0085","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/annonc\/mdn721","article-title":"Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer","volume":"20","author":"Zang","year":"2009","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419392191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419392191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/5\/1001\/649210\/mdp464.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:22:23Z","timestamp":1624519343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419392191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0923753419392191"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdp464","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}